Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Manjari Pandey is active.

Publication


Featured researches published by Manjari Pandey.


Journal of Ovarian Research | 2016

Genomic alterations in neuroendocrine cancers of the ovary

George Yaghmour; Philippe Prouet; Eric Wiedower; Omer Jamy; Rebecca Feldman; Jason C. Chandler; Manjari Pandey; Mike G. Martin

BackgroundAs we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO.MethodsPatients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007–2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes.ResultsForty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12–75] and 26 years [range 8–40], respectively) than patients with NET-O 62 [range 13–76] or SCLC 66 [range 36–86]. SCCO patients were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified.ConclusionsNo recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.


Breast Cancer Research and Treatment | 2018

Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Brennan McCullar; Manjari Pandey; George Yaghmour; Felicia Hare; Kruti Patel; Matthew K Stein; Rebecca Feldman; Jason Claud Chandler; Michael Gary Martin

In the original publication, the sixth author name was published incorrectly as Matthew Stein. The correct author name should read as Matthew K Stein.


Journal of Clinical Oncology | 2011

Hepatoid Carcinoma of the Ovary

Manjari Pandey; Cristina I. Truica


Anticancer Research | 2016

Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors

George Yaghmour; Manjari Pandey; Catherine Ireland; Kruti Patel; Sara Nunnery; Daniel Powell; Scott L. Baum; Eric Wiedower; Lee S. Schwartzberg; Mike G. Martin


Breast Cancer Research and Treatment | 2016

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Brennan McCullar; Manjari Pandey; George Yaghmour; Felicia Hare; Kruti Patel; Matthew K Stein; Rebecca Feldman; Jason C. Chandler; Mike G. Martin


Clinical Breast Cancer | 2015

Grade and prognosis in localized primary angiosarcoma

Manjari Pandey; Gregory R. Sutton; Smith Giri; Mike G. Martin


Journal of Clinical Oncology | 2018

Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM).

Matthew K Stein; Mike G. Martin; Joanne Xiu; Sandeep Mittal; Surasak Phuphanich; Aaron Provenzano; Sharon K. Michelhaugh; Andrew Brenner; Deepa Suresh Subramaniam; Ashley Love Sumrall; Amy B. Heimberger; Santosh Kesari; W. Michael Korn; Manjari Pandey


Neuro-oncology | 2018

P01.058 Higher immune associated markers (PD-L1, PD-1, TMB, MSI) in gliosarcoma compared to glioblastoma.

S Phuphanich; Nader Sanai; Joanne Xiu; Sandeep Mittal; Sharon K. Michelhaugh; Deepa Suresh Subramaniam; Manjari Pandey; Santosh Kesari; Amy B. Heimberger; Zoran Gatalica; W M Korn; A L Sumrall


Journal of Clinical Oncology | 2018

Measuring serum neurofilament light (sNfL) levels to determine correlation with activity of brain metastases (BM) and gliomas (G).

Jason Porter; Madison Boles; Manjari Pandey; Philippe Prouet; Felicia Hare; Syed Sameer Nasir; Henrik Zetterberg; Mike G. Martin


Neuro-oncology | 2017

ACTR-43. TUMOR TREATING FIELD COMPLIANCE AND OVERALL SURVIVAL IN PATIENTS WITH PRIMARY GBM

Manjari Pandey; Kaitlin Qualls; Madison Michael; Jeffrey Sorenson; Brandon Baughman; Enrique W. Izaguirre; Matthew T. Ballo

Collaboration


Dive into the Manjari Pandey's collaboration.

Top Co-Authors

Avatar

Mike G. Martin

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

George Yaghmour

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Kruti Patel

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Matthew T. Ballo

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Brandon Baughman

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Felicia Hare

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Jeffrey Sorenson

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Madison Michael

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Matthew K Stein

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Rebecca Feldman

University of Texas at El Paso

View shared research outputs
Researchain Logo
Decentralizing Knowledge